TEFLARO

Peak

ceftaroline fosamil

NDAINTRAVENOUSPOWDER
Approved
Oct 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
5

Clinical Trials (5)

NCT01789528Phase 1Completed

A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers

Started Aug 2013
48 enrolled
PharmacokineticsOpen LabelCAZ-AVI+3 more
NCT01645735Phase 4Completed

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

Started Oct 2012
49 enrolled
Infections
NCT01499277Phase 3Completed

Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

Started May 2012
802 enrolled
Complicated Skin and Soft Tissue Infection
NCT02582203Phase 4Completed

Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

Started Feb 2012
174 enrolled
Skin Diseases, InfectiousStaphylococcal Skin Infections
NCT01290900Phase 1Completed

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

Started Feb 2011
54 enrolled
Healthy Male Volunteers

Loss of Exclusivity

LOE Date
Feb 10, 2031
60 months away
Patent Expiry
Feb 10, 2031

Patent Records (2)

Patent #ExpiryTypeUse Code
9629861
Sep 21, 2030
Product
8247400
Feb 10, 2031
Product
U-282